Prosecution Insights
Prosecution Insights
10 pending office actions • 10 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §101 + other | 1 (10%) |
| §103 only | 3 (30%) |
| Multi-statute (no §101) | 5 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BALAJ, ANTHONY MICHAEL | 1 | 29.8% | +32.4% |
| FRITH, SEAN A | 1 | 62.1% | +27.0% |
| MERENE, JAN CHRISTOP L | 1 | 68.3% | +48.7% |
| GOLOVAN, MARK | 1 | 100.0% | +0.0% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +44.5% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.7% |
| JOHNSON, KARA D | 1 | 69.1% | +24.6% |
| CANELLA, KAREN A | 1 | 62.1% | +32.9% |
| O'BRIEN, LEA S | 1 | 51.4% | +13.9% |
| SABOKTAKIN, MARJAN | 1 | 57.8% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 16d overdue |
| 19199170 | BOOSTING THE PREDICTIVE POWER OF VIRUS-SPECIFIC T-CELL (VST) CLINICAL TRIALS VIA GENERATIVE MODELS | BALAJ, ANTHONY MICHAEL | — |
| 18259529 | CONNECTION PROTECTOR, SECUREMENT SYSTEM HAVING THE CONNECTION PROTECTOR AND USES THEREOF | GOLOVAN, MARK | — |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | — |
| 17907180 | SARS-COV-2-SPECIFIC T CELLS AND METHODS OF TREATMENT USING THEM | JOHNSON, KARA D | — |
| 17784072 | T-CELL EPITOPES OF HUMAN PARAINFLUENZA VIRUS 3 FOR ADOPTIVE T-CELL IMMUNOTHERAPY | CANELLA, KAREN A | — |
| 17255731 | METHODS AND SYSTEM FOR DYE-FREE VISUALIZATION OF BLOOD FLOW AND TISSUE PERFUSION IN LAPAROSCOPY | SABOKTAKIN, MARJAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 16d overdue |
| 17421337 | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USING THE SAME | O'BRIEN, LEA S | 26d |
| 19199170 | BOOSTING THE PREDICTIVE POWER OF VIRUS-SPECIFIC T-CELL (VST) CLINICAL TRIALS VIA GENERATIVE MODELS | BALAJ, ANTHONY MICHAEL | — |
| 18835259 | ACCESS TOOL FOR DELIVERING CARDIAC THERAPIES TO THE PERICARDIAL SPACE | MERENE, JAN CHRISTOP L | — |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | — |
| 17907180 | SARS-COV-2-SPECIFIC T CELLS AND METHODS OF TREATMENT USING THEM | JOHNSON, KARA D | — |
| 17784072 | T-CELL EPITOPES OF HUMAN PARAINFLUENZA VIRUS 3 FOR ADOPTIVE T-CELL IMMUNOTHERAPY | CANELLA, KAREN A | — |
| 17255731 | METHODS AND SYSTEM FOR DYE-FREE VISUALIZATION OF BLOOD FLOW AND TISSUE PERFUSION IN LAPAROSCOPY | SABOKTAKIN, MARJAN | — |
| Art Unit | Apps |
|---|---|
| 3682 | 1 |
| 3798 | 1 |
| 3773 | 1 |
| 3783 | 1 |
| 1682 | 1 |
| 1638 | 1 |
| 1632 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| 3797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19199170 | BOOSTING THE PREDICTIVE POWER OF VIRUS-SPECIFIC T-CELL (VST) CLINICAL TRIALS VIA GENERATIVE MODELS | BALAJ, ANTHONY MICHAEL | 3682 | §103§112 | Non-Final OA | — | Pending | May 05, 2025 |
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 3798 | §101 | Final Rejection | 16d overdue | Pending | Mar 03, 2025 |
| 18835259 | ACCESS TOOL FOR DELIVERING CARDIAC THERAPIES TO THE PERICARDIAL SPACE | MERENE, JAN CHRISTOP L | 3773 | §103 | Final Rejection | — | Pending | Aug 01, 2024 |
| 18259529 | CONNECTION PROTECTOR, SECUREMENT SYSTEM HAVING THE CONNECTION PROTECTOR AND USES THEREOF | GOLOVAN, MARK | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | 1682 | §101§112 | Non-Final OA | — | Pending | May 03, 2023 |
| 18008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | VIVLEMORE, TRACY ANN | 1638 | §103 | Final Rejection | 28d | Pending | Dec 05, 2022 |
| 17907180 | SARS-COV-2-SPECIFIC T CELLS AND METHODS OF TREATMENT USING THEM | JOHNSON, KARA D | 1632 | §103§112 | Non-Final OA | — | Pending | Sep 23, 2022 |
| 17784072 | T-CELL EPITOPES OF HUMAN PARAINFLUENZA VIRUS 3 FOR ADOPTIVE T-CELL IMMUNOTHERAPY | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2022 |
| 17421337 | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USING THE SAME | O'BRIEN, LEA S | 1646 | §103Other | Non-Final OA | 26d | Pending | Jul 07, 2021 |
| 17255731 | METHODS AND SYSTEM FOR DYE-FREE VISUALIZATION OF BLOOD FLOW AND TISSUE PERFUSION IN LAPAROSCOPY | SABOKTAKIN, MARJAN | 3797 | §103§112 | Non-Final OA | — | Pending | Dec 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial